MEDomics is a privately held molecular diagnostics company that was founded in 2008 with the mission to provide Mutation Expert-based Diagnosis ("MED") of a patient's genome to better allow the physician to deliver personalized treatment. MEDomics was founded by Dr. Steve Sommer MD, PhD, FACMG, an initial member of the American College of Medical Genetics and a pioneer in the analysis of genetic variants that cause disease. MEDomics provides genomic solutions for the diagnosis of mitochondrial and Mendelian diseases using Next Generation Sequencing methodology and custom proprietary bioinformatics pipelines for variant analysis that yield the most in-depth clinical reports in the industry. Our world-class team uses bioinformatics, clinical genetics, and mutation analysis to provide high quality interpretations of genome data, which we believe will lead to improved diagnosis, treatment, and prevention of human disease. MEDomics is recognized as the first lab focused on CLIA Next Generation (NextGen) sequencing for personalized medicine.
MEDomics announces new enhanced testing of nuclear genes related to mitochondrial disease, autism, epilepsy and intellectual disability.
Copyright © 2013 MEDomics